PRELID2 and hepatocellular carcinoma: Interestingly, we found that HCC patients with P53 mutations exhibited a higher level of PRELID2 than patients with P53 non-mutant (P < 0.001, Additional file 1: Fig. S5d), suggesting a tumor-promoting role of PRELID2 in HCC.